Roozen, G.V.T.; Sukwa, N.; Chirwa, M.; White, J.A.; Estrada, M.; Maier, N.; Turbyfill, K.R.; Laird, R.M.; Suvarnapunya, A.E.; Sayeh, A.;
et al. Safety, Tolerability, and Immunogenicity of the InvaplexAR-Detox Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial. Vaccines 2025, 13, 48.
https://doi.org/10.3390/vaccines13010048
AMA Style
Roozen GVT, Sukwa N, Chirwa M, White JA, Estrada M, Maier N, Turbyfill KR, Laird RM, Suvarnapunya AE, Sayeh A,
et al. Safety, Tolerability, and Immunogenicity of the InvaplexAR-Detox Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial. Vaccines. 2025; 13(1):48.
https://doi.org/10.3390/vaccines13010048
Chicago/Turabian Style
Roozen, Geert V. T., Nsofwa Sukwa, Masuzyo Chirwa, Jessica A. White, Marcus Estrada, Nicole Maier, Kevin R. Turbyfill, Renee M. Laird, Akamol E. Suvarnapunya, Aicha Sayeh,
and et al. 2025. "Safety, Tolerability, and Immunogenicity of the InvaplexAR-Detox Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial" Vaccines 13, no. 1: 48.
https://doi.org/10.3390/vaccines13010048
APA Style
Roozen, G. V. T., Sukwa, N., Chirwa, M., White, J. A., Estrada, M., Maier, N., Turbyfill, K. R., Laird, R. M., Suvarnapunya, A. E., Sayeh, A., D’Alessio, F., Marion, C., Pattacini, L., Hoogerwerf, M.-A., Murugan, R., Terrinoni, M., Holmgren, J. R., Sirima, S. B., Houard, S.,
... Roestenberg, M.
(2025). Safety, Tolerability, and Immunogenicity of the InvaplexAR-Detox Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial. Vaccines, 13(1), 48.
https://doi.org/10.3390/vaccines13010048
